Thirty years of research on the biology of posttraumatic stress disorder now provides a foundation for hypotheses related to the mechanisms underlying the pharmacotherapy of this disorder. Only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration for the treatment of PTSD. Although these medications are somewhat effective, other treatment mechanisms must be explored to address the unmet need for effective treatment. This article provides a concise summary of advances in our understanding of the neurobiology of PTSD and novel approaches to pharmacotherapy.
|Number of pages||17|
|Journal||Clinical Psychology: Science and Practice|
|State||Published - Sep 2017|
Bibliographical notePublisher Copyright:
Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
- gamma-amino-butyric acid
- posttraumatic stress disorder
ASJC Scopus subject areas
- Clinical Psychology